You are here: Industry Insights > Lilly

News List

Lilly's Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials drugs
August 25, 2021
Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3.
Lilly, Boehringer's Jardiance bags FDA approval for heart failure firstwordpharma
August 19, 2021
The FDA has expanded the label for Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) to include reducing the risk of cardiovascular death plus hospitalisation for heart failure (HF) in adult patients with reduced ejection fraction (HFrEF).
NICE recommends Eli Lilly’s breast cancer drug Verzenios pharmatimes
August 13, 2021
Draft NICE guidance has recommended Eli Lilly’s twice-daily pill Verzenios (abemaciclib) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology prnasia
August 06, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company today ...
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation worldpharmanews
August 04, 2021
Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who ...
Lilly-Incyte’s baricitinib lowers mortality in Phase III Covid-19 trial pharmaceutical-technology
August 04, 2021
Eli Lilly and Incyte have reported new data from Phase III COV-BARRIER sub-study, where baricitinib lowered mortality risk in Covid-19 patients receiving mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Lilly Releases Donanemab Data That Demonstrated Relationship Between Reduction of Amyloid Plaque and Slowing of Cognitive Decline drugs
August 02, 2021
Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study.
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy pharmaceutical-technology
July 30, 2021
The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Eli Lilly and Incyte’s drug, baricitinib, for Covid-19 treatment with or without remdesivir.
Lilly to acquire biotech company Protomer Technologies europeanpharmaceuticalreview
July 22, 2021
Eli Lilly and Company has announced the acquisition of California-based biotech company, Protomer Technologies.
Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly prnasia
July 22, 2021
A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical company, announced today the completion of its acquisition of Cialis® in the People's Republic of China from Eli Lilly and Company.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page